This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
-
Mayo Clinical, Phoenix, Arizona, United States, 85054
City of Hope Medical Center, Duarte, California, United States, 91010
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States, 90033
HOAG Memorial Hospital Presbyterian, Newport Beach, California, United States, 92663
Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California, United States, 90404
Stanford Health Care, Stanford, California, United States, 94305
Yale University, New Haven, Connecticut, United States, 06520-8032
Georgetown University Medical Center, Washington, District of Columbia, United States, 20007
Mayo Clinical, Jacksonville, Florida, United States, 32224
University of Miami, Miami, Florida, United States, 33136
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Vyriad, Inc.,
Alice Bexon, MD, STUDY_CHAIR, CMO
Stephen J Russell, MD, Ph.D., STUDY_DIRECTOR, Clinical Lead
2025-03